Transforming the Funding of Life Sciences Through Collaborative Capital

Royalty Pharma

Transforming the Funding
of Life Sciences Through
Collaborative Capital

Engage With Us

We work directly with innovators across
the life sciences, including research
institutions, inventors, and biopharma

Royalty Monetization


Our strategy is simple: we acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of our diversified portfolio.


We work with drug developers to invest directly in late-stage clinical trials across all therapeutic areas. We prioritize alignment with our partners throughout the pharmaceutical life cycle by sharing in clinical development, regulatory approval and commercialization.



We take a flexible approach to acquisitions and in-licensing transactions. Allowing companies to focus their resources on strategic assets, Royalty Pharma is the ideal partner for biopharma M&A.


The quality and scale of Royalty Pharma’s portfolio of pharmaceutical royalties is unparalleled in the industry. Since 1996, we have meticulously acquired royalty interests in many of the industry’s leading drugs by sales addressing serious unmet medical needs.

Management Team

Pablo L.

Pablo Legorreta

Founder & Chief Executive Officer
Jim Reddoch

Jim Reddoch

Executive Vice President, Head of Research & Investments
Portrait of Christopher Hite

Christopher Hite

Executive Vice President & Vice Chairman
George Lloyd

George Lloyd

Executive Vice President, Investments & General Counsel
Portrait of Terrance Coyne

Terrence Coyne

Chief Financial Officer


Since 1996, Royalty Pharma has expanded the traditional parameters that define a pharmaceutical company. Our disciplined focus, deep fundamental diligence, and collaborative approach to investing, makes us the global leader in the acquisition of pharmaceutical royalty interests.